From a salutogenic perspective, the non-motor symptoms observed here—constipation, depression, and REM sleep behavior disorder (RBD)—can be understood as markers of reduced compensatory reserve, which might reflect the nervous system’s inability to buffer the effects of α-synuclein pathology and neuroinflammation. This evidence concerns the gene SNCA and depressive symptom measurement.